First Light Asset Management LLC Has $9.91 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

First Light Asset Management LLC decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 66.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 420,431 shares of the company's stock after selling 836,854 shares during the period. Dyne Therapeutics accounts for about 0.9% of First Light Asset Management LLC's holdings, making the stock its 28th largest position. First Light Asset Management LLC owned about 0.41% of Dyne Therapeutics worth $9,905,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. KBC Group NV boosted its stake in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares during the period. Summit Investment Advisors Inc. increased its position in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after acquiring an additional 721 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Dyne Therapeutics during the 4th quarter valued at $257,000. Magnetar Financial LLC bought a new stake in Dyne Therapeutics in the 4th quarter valued at $263,000. Finally, E Fund Management Co. Ltd. grew its position in Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after purchasing an additional 1,249 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Down 1.1 %

DYN traded down $0.13 during trading on Friday, hitting $11.86. The company's stock had a trading volume of 1,040,609 shares, compared to its average volume of 1,555,082. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -3.33 and a beta of 1.21. The firm's 50 day moving average price is $10.62 and its two-hundred day moving average price is $19.13. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on DYN. HC Wainwright reiterated a "buy" rating and issued a $46.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. Scotiabank began coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Chardan Capital restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Finally, BMO Capital Markets started coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $47.46.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have sold 6,237 shares of company stock worth $77,760. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.